Search results
Promising trial data for Moderna's skin cancer vaccine sends stock rising
Quartz· 20 hours agoModerna stock jumped nearly 4% on Tuesday after the the company announced positive data from an...
Proton therapy demonstrates advantages over traditional radiation therapy in Phase III head and neck...
Medical Xpress· 18 minutes agoAccording to preliminary data from a multi-institution Phase III trial led by researchers at The...
FDA advisers consider MDMA therapy to treat PTSD
KETV 7 Omaha· 1 hour agoA federal advisory committee meets on Tuesday to weigh the risks and benefits of using MDMA, commonly known as ecstasy, as a treatment for post-traumatic...
Bristol Myers Squibb’s Breyanzi shows promise in B-cell malignancy clinical trials
Clinical Trials Arena via Yahoo Finance· 5 hours agoUS-based pharmaceutical company Bristol Myers Squibb (BMS) has published data from three studies in...
ASCO 2024: Alligator shares positive data for pancreatic cancer drug
Pharmaceutical Technology via Yahoo Finance· 32 minutes agoHe adds that approved therapies are quite “mediocre” in terms of response rate and clinical benefit....
Genmab and BioNTech report data from Phase II GCT1046-04 trial for mNSCLC
Clinical Trials Arena via Yahoo Finance· 1 day agoGenmab and BioNTech announced the initial data from the phase II GCT1046-04 trial, which evaluated...
The Gold Rush for Weight Loss Drugs Is Here. These 3 Latecomers Could Be Worth a Buy.
Motley Fool via Yahoo Finance· 1 day agoThree aspiring contenders are raring to go, and they might even be able to claim the crown...'s...
Moderna and MSD share encouraging three-year data from trial of melanoma therapy
Clinical Trials Arena via Yahoo Finance· 7 hours agoIn December 2023, the two companies enrolled the first subjects in the Phase III INTerpath-002 study...
ASCO: After Keytruda, Merck builds 3-pronged cancer strategy starring Moderna-partnered vaccine
FierceBiotech· 1 day agoKeytruda’s 2028 patent cliff looms large, Merck & Co.’s renewed R&D oncology strategy focuses on ...
Here Are 3 More Reasons to Be Bullish on Ozempic and Novo Nordisk Stock
Motley Fool via Yahoo Finance· 1 hour agoThe pieces are already in motion The final reason to be bullish about Ozempic, and by proxy bullish...